RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

The RAPS store will be under maintenance Saturday, 13 June between 6 AM and 12 PM EST. Store functionality may be unavailable at times during this window.
We apologize for any inconvenience caused during this time.

Regulatory Focus™ > News Articles > 6 > FDA Adopts ICH Guideline on Nonclinical Evaluation for Anticancer Drugs

FDA Adopts ICH Guideline on Nonclinical Evaluation for Anticancer Drugs

Posted 15 June 2018 | By Michael Mezher 

FDA Adopts ICH Guideline on Nonclinical Evaluation for Anticancer Drugs

With the publication of a final guidance on Friday, the US Food and Drug Administration (FDA) has adopted the International Council for Harmonization's (ICH) questions and answers guideline on the nonclinical evaluation of drugs intended to treat cancer.
The final guidance comes less than two months after ICH advanced the document for international implementation in late April.
The guideline, which contains 41 questions and answers aimed at providing additional clarity about oncology drug development, is meant to be read alongside ICH's 2009 guideline S9 Nonclinical Evaluation for Anticancer Pharmaceuticals.
In 2014, ICH formed a working group to develop the questions and answers guideline after finding that many of the aspects covered by ICH S9 were "open to broad and divergent interpretation by both regulatory authorities and industry."
In addition to providing greater clarity on anticancer drug development, FDA says the questions and answers guideline will help with progress toward the 3Rs: reduction, refinement and replacement in the use of animals in drug development.
FDA also says the guideline has been updated since the draft questions and answers were first circulated to provide greater clarity and delete certain questions "due to a lack of harmonization.”
In particular, FDA says the final version of the guideline provides greater clarity on its scope, additional recommendations on developing antibody-drug conjugates and the need for recovery animals in general toxicology studies.
Guidance, Federal Register Notice

Regulatory Focus newsletters

All the biggest regulatory news and happenings.